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http://www.actaneurocomms.org/content/2/1/48RESEARCH Open AccessNeuromyelitis optica pathology in rats following
intraperitoneal injection of NMO-IgG and
intracerebral needle injury
Nithi Asavapanumas and AS Verkman*Abstract
Introduction: Animal models of neuromyelitis optica (NMO) are needed for drug testing and evaluation of NMO
disease pathogenesis mechanisms.
Results: We describe a novel passive-transfer model of NMO in which rats made seropositive for human
anti-aquaporin-4 (AQP4) immunoglobulin G antibody (NMO-IgG) by intraperitoneal (IP) injections were subject to
intracerebral needle injury. Following a single IP injection, NMO-IgG distributed rapidly to peripheral AQP4-expressing
cells (kidney collecting duct, gastric glands, airways, skeletal muscle) and area postrema in brain, but not elsewhere in
the central nervous system; however, no pathology was seen in brain, spinal cord, optic nerve or peripheral tissues.
After testing various maneuvers to produce NMO-IgG-dependent pathology in brain, we found that transient puncture
of brain parenchyma with a 28-gauge needle in NMO-IgG seropositive rats produced robust NMO pathology around the
needle track, with loss of AQP4 and glial fibrillary acidic protein, granulocyte and macrophage infiltration, centrovascular
deposition of activated complement, and blood–brain barrier disruption, with demyelination by 5 days. Pathology was
not seen in rats receiving control (non-NMO) human IgG or in NMO-IgG-seropositive rats made complement-deficient
by cobra venom factor. Interestingly, at 1 day a reversible, multifocal astrocytopathy was seen with loss of AQP4 and
GFAP (but not myelin) in areas away from the needle track.
Conclusions: NMO-IgG-seropositivity alone is not sufficient to cause NMO pathology in rats, but a single intracerebral
needle insertion, without pre-existing inflammation or infusion of pro-inflammatory factors, was sufficient to produce
robust NMO pathology in seropositive rats.
Keywords: NMO, Aquaporin-4, Astrocyte, Complement, NeuroinflammationIntroduction
Neuromyelitis optica (NMO) is an inflammatory demye-
linating disease of the central nervous system that can
produce motor and visual impairment [1-3]. Most NMO
patients are seropositive for immunoglobulin G auto-
antibodies (NMO-IgG) directed against aquaporin-4
(AQP4) [4,5], a water channel expressed in the plasma
membrane of astrocytes in brain, spinal cord and optic
nerve [6,7]. Though AQP4 is also expressed in some
peripheral tissues, including kidney collecting duct, gas-
tric glands, airway epithelia and skeletal muscle [8,9],
significant pathology is absent in peripheral tissues in* Correspondence: Alan.Verkman@ucsf.edu
Departments of Medicine and Physiology, University of California, San
Francisco, CA, USA
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article, unless otherwise stated.NMO [3]. NMO lesions in the human central nervous
system show astrocyte damage with loss of AQP4 and
glial fibrillary acidic protein (GFAP), inflammation with
granulocyte and macrophage infiltration, vasculocentric
deposition of activated complement, blood–brain barrier
disruption and demyelination [4,5,10-12]. There is a sub-
stantial body of evidence supporting a pathogenesis
mechanism in which NMO-IgG binding to astrocytic
AQP4 produces complement-dependent cytotoxicity
(CDC), which leads to inflammation and blood–brain
barrier disruption with secondary oligodendrocyte injury,
demyelination and neuronal injury [13-15]. Antibody-
dependent cellular cytotoxicity (ADCC) also plays a role
[16], as does, perhaps, AQP4-sensitized T cells or other
factors promoting blood–brain barrier breakdown [17-19].BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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models of NMO for investigation of disease pathogenesis
mechanisms and testing therapeutics [20,21]. The ori-
ginal animal models involved intraperitoneal injection of
IgG purified from NMO patient serum in rats with pre-
existing inflammation produced by sensitization to mye-
lin oligodendrocyte protein (experimental autoimmune
encephalomyelitis, EAE) [22-24] or by complete Freund’s
adjuvant [25]. In these models greater CNS inflamma-
tion was seen in rats receiving NMO-IgG, with evidence
for astrocyte damage and complement activation. How-
ever, the pre-existing inflammation in these models
confounds data interpretation because NMO involves
astrocyte-targeted antibodies rather than sensitized T
cells.
Mouse models of NMO involving intracerebral injection
or infusion of NMO-IgG and human complement have
been informative in studying disease pathogenesis mecha-
nisms, such as the roles of ADCC [26,16] and of various
leukocyte types [27-29]. Brain pathology in injected mice
is similar to NMO pathology in humans, with loss of
AQP4, GFAP and myelin, granulocyte and macrophage
infiltration, and complement deposition [19]. In recent
advances, including the use of NMO superantibodies with
increased CDC/ADCC effector function(s) and CD59
knockout mice, optic neuritis [30] and longitudinally
extensive transverse myelitis [31] have been produced in
mice by passive transfer of NMO-IgG and human comple-
ment. However, all mouse models require direct adminis-
tration of human complement into the central nervous
system, as the mouse complement system is ineffective
because, in part, of circulating complement-inactivating
protein(s) [32].
To overcome the limitations of existing models, and
building on methods developed in mice, we recently re-
ported a rat model of NMO involving intracerebral injec-
tion of NMO-IgG, without complement supplementation
and without pre-existing neuroinflammation [33]. Unlike
mice, rats have an active complement system similar to
humans. The NMO-IgG injected rats developed charac-
teristic NMO pathology around the needle track, which
was complement-dependent. The model was applied to
investigate the role of ADCC and macrophages in NMO
pathogenesis.
A limitation of our reported rat model [33] was the
need to inject NMO-IgG directly into the brain, which
is different from human NMO in which NMO-IgG is
present in serum and pathology is initiated, in large part,
following NMO-IgG entry into the central nervous sys-
tem. Testing of certain therapeutics, such as aquaporu-
mab antibodies [34], IgG inactivation therapies [35,36]
and complement-targeted drugs [37,38], are best done in
models of NMO in which pathology is produced in sero-
positive animals. Motivated by this need, the goal of thisstudy was to establish a robust of NMO in rats made
NMO-IgG-seropositive by peripheral NMO-IgG adminis-
tration. We first studied the tissue distribution and serum
pharmacokinetics of peripherally administered NMO-IgG
in rats, and then established the minimal conditions in
which robust NMO pathology could be produced in sero-
positive rats.
Materials and methods
Rats
Lewis rats were purchased from Charles River Lab
(Wilmington, MA). Experiments were done using weight-
matched rats (150–250 g), age 8 to 12-weeks. Protocols
were approved by the University of California San
Francisco Committee on Animal Research.
Antibodies and sera
A recombinant monoclonal NMO antibody, rAb-53 (re-
ferred to as NMO-IgG), was generated from a clonally
expanded plasma blast population from cerebrospinal
fluid of an NMO patient, as described and characterized
previously [22,39]. NMO serum was obtained from sero-
positive individuals who met the revised diagnostic cri-
teria for clinical disease [3]. Non-NMO (seronegative)
human serum was used as control. In some studies IgG
was purified from NMO or control serum using Protein
A-resin (GenScript, Piscataway, NY) and concentrated
using Amicon Ultra Centrifugal Filter Units (Millipore,
Billerica, MA).
Cell culture and cytotoxicity assay
Chinese hamster ovary (CHO) cells stably expressing hu-
man M23-AQP4 [40] were cultured at 37°C in 5% CO2
95% air in F-12 Ham’s Nutrient Mixture medium supple-
mented with 10% fetal bovine serum, 200 μg/ml geneticin
(selection marker), 100 U/ml penicillin and 100 μg/ml
streptomycin. For assay of complement-dependent cyto-
toxicity (CDC) in seropositive rats, cells were plated on
96-well microplates, washed with phosphate-buffered sa-
line (PBS) and incubated at 28°C for 60 min with different
concentration of heat-inactivated rat serum and 5% hu-
man complement (Innovative Research, Novi, MI) in a
total volume of 50 μl. Cytotoxicity was measured by the
Alamar Blue assay (Invitrogen). In some experiment, the
activity of rat complement was measured by incubating
5% rat serum plus 10 μg NMO-IgG in M23-AQP4 ex-
pressing CHO cells.
Pharmacokinetics and tissue distribution
Adult rats received 750 μg of NMO-IgG (or control IgG)
in PBS by intraperitioneal injection in a total volume of
500 μl. Blood was collected through the tail vein at 1, 2, 4,
6, 8, 24 and 48 h, left for 30 min at room temperature to
allow clotting, and centrifuged for 10 min at 3000 g, 4°C.
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was determined using a human IgG ELISA kit (GenWay,
San Diego, CA). For analysis of tissue distribution, at 24 h
after injection rats were anesthetized using ketamine
(75–100 mg/kg) and xylazine (5–10 mg/kg) and perfused
with PBS and then PBS containing 4% paraformaldehyde
(PFA). AQP4-expressing tissues were removed, post-fixed
overnight in 4% PFA and dehydrated overnight in 30%
sucrose. Tissues were embedding in OCT compound
(Sakura Finetek, Torrance, CA) for sectioning and
immunostaining.
NMO-IgG delivery and intracerebral needle injury
Adult rats were administered 1 mg NMO-IgG (or control
IgG) in a volume of 500 μl 6 h before and 24 h after intra-
cerebral needle injury. To create the needle injury, rats were
anesthetized with intraperitoneal ketamine (75–100 mg/kg)
and xylazine (5–10 mg/kg) and mounted in a stereotaxic
frame. Following a midline scalp incision, a burr hole of
diameter 1 mm was made in the skull 3.5 mm to the right
of the bregma. A 28-gauge needle attached to 10-μl gas-
tight glass syringe (Hamilton, Reno, NV) was inserted
5 mm deep to infuse 10 μl of PBS (at 2 μl/min). After 1 or
5 days, rats were anesthetized and perfused through the left
cardiac ventricle with 100 ml PBS and then 25 ml of PBS
containing 4% PFA. In some studies rat complement was
depleted by intraperitoneal injection of cobra venom factor
(350 U/kg; Quidel Corporation, Santa Clara, CA) [41,42]
24 h before and 48 h after intracerebral needle injury.
Immunofluorescence
Five micrometer-thick paraffin sections were immuno-
stained at room temperature for 1 h with antibodies against
rat AQP4 (1:200, Santa Cruz Biotechnology), GFAP (1:100,
Millipore), myelin basic protein (MBP) (1:200, Santa Cruz
Biotechnology), ionized calcium-binding adaptor mole-
cule-1 (Iba1; 1:1,000; Wako), albumin (1:200, Santa Cruz
Biotechnology), Ly-6G (1:100, Santa Cruz Biotechnology),
C5b-9 (1:50, Hycult Biotech), CD45 (1:10, BD Biosciences),
CD163 (1:50, Bio-Rad Laboratories), neurofilament (1:200,
Millipore), iNOS (1:100, BD Biosciences) or arginase-1
(1:50, Santa Cruz Biotechnology), followed by appropriate
fluorescent secondary antibody (1:200, Invitrogen) or bio-
tinylated secondary antibody (1:500, Vector Laboratories).
Tissue sections were examined with a Leica (Wetzlar,
Germany) DM 4000 B microscope. AQP4, GFAP and MBP
immunonegative areas were defined by hand and quantified
using ImageJ. Data are presented as area (mm2) of immu-
nonegative area.
Statistical analysis
Comparisons between two groups were performed using
an unpaired t-test. P < 0.05 was considered statistically
significant. Values are presented as mean ± S.E.Results
NMO-IgG pharmacokinetics and tissue distribution
following IP injection
The pharmacokinetics of NMO-IgG in rats was deter-
mined following a single intraperitoneal injection of
750 μg of NMO-IgG (recombinant human monoclonal
antibody rAb-53) or control (non-NMO) human IgG.
Human IgG concentration in rat serum was assayed by
ELISA against human IgG, which is not sensitive to rat
IgG. Figure 1A shows human IgG concentration in rat
serum over 48 h. NMO-IgG concentration increased
over the first few hours as it was absorbed from the peri-
toneal cavity, was maximum at ~6 h, and then decreased
with t1/2 ~ 48 h. The higher levels seen for an equivalent
amount of control (non-NMO) IgG are probably related
to binding of NMO-IgG in AQP4-expressing tissues.
The tissue distribution of injected NMO-IgG was deter-
mined by immunofluorescence in which fixed tissues were
immunostained for AQP4 using an anti-AQP4 antibody
and for NMO-IgG using an anti-human fluorescent se-
condary antibody. Figure 1B shows colocalization of
NMO-IgG and AQP4 in the basolateral membrane of kid-
ney inner medullary collecting duct epithelial cells, the
basolateral membrane of gastric parietal cells, the baso-
lateral membrane of tracheal surface epithelial cells, and
the plasmalemma in skeletal muscle. Immunofluorescence
with the anti-human secondary antibody was negative in
rats receiving control IgG. C5b-9 immunofluorescence
was negative in each tissue, indicating absence of depo-
sition of activated complement. A similar pattern, though
with less intense NMO-IgG staining, was seen at 2 h after
injection (not shown).
Figure 1C shows absence of NMO-IgG deposition at
24 h in retina, brain, spinal cord and optic nerve – CNS
tissues in which AQP4 is expressed in retinal Muller
cells, and astrocytes in brain, spinal cord and optic
nerve. By an extensive search of sections from these tis-
sues we found NMO-IgG in circumventricular organs,
including area postrema (Figure 1D), which lack an in-
tact blood brain barrier. However, deposition of activated
complement was not seen (Figure 1D), nor was there
evidence of NMO pathology with loss of AQP4, GFAP
or myelin (not shown).
NMO model in NMO-IgG seropositive rats
Because neither NMO-IgG deposition nor NMO patho-
logy was seen in the initial studies, several approaches
were tested to produce NMO pathology in rats. An
NMO-IgG administration protocol was first established to
produce sustained seropositivity in rats. Rats were admi-
nistered NMO-IgG (or control IgG) (1 mg) by intraperito-
neal injection at days 0 and 1 (Figure 2A, top). To confirm
seropositivity, rat serum obtained at 8 and 24 h was bios-
sayed for CDC in vitro in which different concentrations
Figure 1 Pharmacokinetics and tissue distribution of NMO-IgG following IP injection. A. Serum concentration of human IgG quantified by
ELISA at 1, 2, 4, 6, 8, 24 and 48 h after intraperitoneal injection of NMO-IgG or control IgG (each 750 μg) (S.E., 3 rats per group). B. Tissue distribution of
NMO-IgG at 24 h after injection of NMO-IgG or control IgG. AQP4 immunofluorescence (green), human IgG (with secondary anti-human antibody, red)
and activated complement (C5b-9). Arrows indicate basolateral membrane in kidney inner medullary collecting duct epithelial cells, basolateral
membrane of gastric parietal cells, basolateral membrane of tracheal surface epithelial cells, and the plasmalemma in skeletal muscle. C. AQP4 and
human IgG staining in retina, brain, spinal cord and optic nerve in same rats as in B. D. AQP4, human IgG and C5b-9 staining in area postrema in same
rats as in B.
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plement), were incubated with AQP4-expressing CHO
cells in the presence of 5% human complement. Figure 2A
(bottom) shows strong seropositivity in the NMO-IgG-
treated rats, with greater cytotoxicity in rat serum at 8 and
24 h than that produced by (heat-inactivated) pooled hu-
man sera from seropositive NMO patients in the presence
of added 5% human complement. No cytotoxicity was
seen in serum from rats injected with control (non-NMO)
IgG.
After evaluating different approaches to produce ro-
bust NMO pathology in NMO-IgG seropositive rats,
including stab injury by a surgical blade, osmotic pumpdelivery, cortical freeze injury and others, we found that
a single intracerebral needle injury produced NMO
pathology after 5 days. A 5-day protocol (Figure 2A, top)
was used in which an intracerebral needle injury (5-min
insertion of a 28-gauge needle with infusion of 10 μl
PBS) was created 6 h after intraperitoneal NMO-IgG
administration, and followed 18 h later by a second
NMO-IgG administration. Figure 2B shows that NMO-
IgG entered rat brain parenchyma at 1 day following
the intracerebral needle injury in this model, with
localization near the needle track and in some structures
away from the needle track. At high magnification the
distribution of NMO-IgG overlapped with that of AQP4,
Figure 2 NMO pathology in seropositive rats at 5 days after intracerebral needle injury. A. (top) NMO-IgG administration and intracerebral
needle injury protocol. (bottom) Rats received 1 mg NMO-IgG or control IgG by intraperitoneal injection. Cytotoxicity in rat serum obtained at 8 and
24 h was measured by Alamar blue assay in AQP4-expressing CHO cells at 1 h after incubation with different concentration of heat-inactivated rat
serum and 5% human complement (S.E., n = 3). For comparison data shown for heat-inactivated pooled human sera from NMO seropositive patients
to which 5% human complement was added. B. (left) AQP4 and human IgG staining in brain of rats receiving NMO-IgG at 1 day after intracerebral
needle injury. Needle track shown as yellow line. (right) Higher magnification of boxed region along with data for control IgG. C. (left) AQP4, GFAP and
MBP immunofluorescence at 5 days. Needle track shown as yellow line and lesion demarcated by white dashed line. (middle) Higher magnification.
(right) Summary the areas of loss of AQP4, GFAP and MBP immunostaining. Each point is from a different rat.
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pillaries. No AQP4 binding was seen in rats receiving
control IgG.
Pathology with characteristic features of NMO was
seen in rats at 5 days after NMO-IgG administration,
with loss of AQP4, GFAP and myelin (MBP) immuno-
fluorescence around the needle track (Figure 2C, left).
At high magnification the area of AQP4, GFAP and
MBP loss was well-demarcated. Pathology was not seen
in rats administered control IgG. Figure 2C (right) sum-
marizes the areas of loss of staining.
Characterization of rat NMO model
In addition to loss of AQP4 and GFAP, other characteristic
features of NMO pathology include demyelination with
axon preservation, blood–brain barrier disruption, micro-
glial activation, centrovascular deposition of activatedcomplement, and granulocyte and macrophage infiltra-
tion. Figure 3A shows a typical demylinating lesion at
5 days as seen by loss of MBP immunofluorescence but
preservation of axons as seen by neurofilament im-
munofluorescence. Substantial blood–brain barrier dis-
ruption was seen in the NMO-IgG treated rats as seen
by albumin extravasation around the needle track
(Figure 3B). Iba1 immunofluorescence showed activated
microglia as well as macrophage infiltration in the
NMO-IgG treated rats (Figure 3C). Most macrophages
were positive for arginase-1 but not iNOS, suggesting
predominantly M2-type macrophages at 5 days.
Figure 3D (left) shows H&E staining and immunocy-
tochemistry for activated complement and leukocyte
markers. The lesion (with reduced AQP4 and GFAP
staining) showed inflammation on H&E staining, vascu-
locentric deposition of activated complement (C5b-9),
Figure 3 Inflammation and blood–brain barrier disruption in the NMO rat model. A. MBP and neurofilament (NF) immunofluorescence
at 5 days in rats treated as in Figure 2. White line demarcates the lesion. B. Albumin immunofluorescence shown with quantification of
immunopositive area (S.E., n = 3). C. Iba1, iNOS (M1-macrophage marker) and arginase-1 (M2-macrophage marker) immunofluorescence. D. (left)
Hematoxylin and eosin (H&E) staining, and immunofluorescence for activated complement (C5b-9), leukocytes (CD45), neutrophils (Ly6-G) and
macrophages (CD163) in brain at 5 days. (right) Summary of the number of infiltrating cells per 0.01 mm2 (S.E., 3 rats).
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neutrophils (Ly-6G) and macrophages (CD163). The
contralateral hemisphere (and rats receiving control an-
tibody, not shown) were negative for each of these
markers. Figure 3D (right) summarizes the number of
CD45-positive cells per 0.01 mm2 in lesions, which con-
tained more macrophages than neutrophils.
To study the early development of pathology in this
model, rats receiving NMO-IgG or control antibody
were sacrificed at 1 day after needle injury. Figure 4A
shows early astrocyte damage seen as loss of AQP4 and
GFAP immunofluorescence, but without myelin loss.
Interestingly, multiple small lesions were seen in the
general vicinity of the needle track at 1 day, though
albumin extravasation was confined to the area directly
around the needle track. Pathology was not seen in rats
receiving control IgG. Figure 4B shows deposition of
activated complement at 1 day with little infiltration
of inflammatory cells. The presence of multiple areas ofloss of AQP4 and GFAP at 1 day away from the needle
track suggests a reversible astrocytopathy that does
not progress, perhaps because inflammatory cells have
limited access to the more distant nascent lesions.
The characteristic NMO pathology produced by the
recombinant NMO-IgG was also seen following intra-
peritoneal injection of IgG purified from NMO patient
serum. The amount of injected purified IgG was chosen
to give a similar concentration as in human serum. In
vivo CDC produced by serum of rats injected with IgG
purified from NMO patient was greater than that pro-
duced by pooled human sera from seropositive NMO
patients (Figure 4C). Cytotoxicity was not seen in rats
injected with control (non-NMO) IgG. Figure 4D shows
significant loss of AQP4, GFAP and MBP immunofluo-
rescence at 5 days after two injections of 75 mg IgG
purified from NMO patient serum, which was not seen
in rats receiving the same amount of IgG from control
(non-NMO) human serum.
Figure 4 Early NMO pathology and NMO pathology produce from NMO patient serum. A. AQP4, GFAP, MBP and albumin immunofluorescence
in rat brain at 1 day after intraperitoneal injection of NMO-IgG and intracerebral needle injury. B. Staining for activated complement (C5b-9), leukocytes
(CD45), neutrophils (Ly6-G) and macrophages (CD163) at 1 day. C. Rats were administered 75 mg of purified IgG from NMO patient serum (or non-NMO
control serum) as in Figure 2A (top). In vitro cytotoxicity of rat serum obtained at 8 h measured in AQP4-expressing CHO cells by Alamar blue assay as
in Figure 2A (bottom) (S.E., n = 3). D. (Left) AQP4, GFAP and MBP immunofluorescence at 5 days in rats administered purified IgG from NMO patients (or
control non-NMO IgG). (right) Summary the areas loss of AQP4, GFAP and MBP (S.E., 4 rats).
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complement-dependent
To confirm the involvement of complement in produ-
cing NMO pathology our model, rat complement was
inactivated with cobra venom factor, a well-established
approach to study the involvement of complement in
various disease processes [41,42]. Rats received cobra
venom factor by intraperitoneal injection 1 day before
and 2 days after intraperitoneal IgG delivery, as dia-
grammed (Figure 5A, top). Figure 5A (bottom) con-
firmed the loss of complement activity in rat serum in
this protocol, as shown using an in vitro CDC assay in
which AQP4-expressing CHO cells were incubated with
NMO-IgG and rat serum. Figure 5B shows absence of
NMO pathology in the cobra venom factor-treated sero-
positive rats, while robust pathology was seen in control(saline) treated seropositive rats, supporting the require-
ment for active rat complement in this model.
Discussion
The goal of this work was to develop a minimally intru-
sive, robust model of NMO in NMO-IgG seropositive
rats. Pharmacokinetic analysis showed that human IgG
was effectively absorbed in rats following IP injection,
and that the t1/2 for NMO-IgG disappearance in blood
was ~48 hours. A convenient NMO-IgG dosing regimen
was established to maintain rat seropositivity at a level
at least as high as that in typical seropositive NMO
patients, as verified by a serum cytotoxicity bioassay.
Though intravenous NMO-IgG administration could
also be used to maintain seropositivity in rats, IP admi-
nistration is technically easier, particularly when many
Figure 5 NMO pathology in seropositive rats is complement-dependent. A. (top) Experimental protocol. (bottom) Cytotoxicity in
AQP4-expressing CHO cells incubated with 10 μg/ml NMO-IgG and 5% serum from cobra venom factor (and control saline) treated rats (S.E.,
n = 3, ** P < 0.01). B. AQP4, GFAP and MBP immunofluorescence at 5 days.
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is needed. NMO-IgG administration by mini-pump,
though not tested, might also be suitable if subcuta-
neously delivered antibody is efficiently absorbed.
Tissue distribution studies showed rapid binding of IP-
administered NMO-IgG to peripheral AQP4-expressing
cells in kidney, stomach, trachea and skeletal muscle, as
was found previously in NMO-IgG-injected mice [43].
NMO-IgG was also seen in AQP4-expressing cells in the
area postrema of brain, which lacks a blood–brain bar-
rier, but not elsewhere in the central nervous system in-
cluding spinal cord and optic nerve. Remarkably, though
serum complement activity in rats is comparable to that
in humans, no pathology was seen in peripheral AQP4-
expressing organs or in circumventricular organs, such
as area postrema in brain. The reason(s) why peripheral
organs are spared in NMO are not clear; it has been
speculated that the specialized environment in central
nervous system tissues may be responsible, as might the
differential expression of complement inhibitor proteins,
such as CD55 and CD59, in central nervous system ver-
sus peripheral tissues [44-47]. The absence of pathology
in circumventricular organs in brains of seropositive rats
suggests that the initiation of NMO pathogenesis re-
quires some additional insult, perhaps local inflam-
mation. Of note, humans may be seropositive for many
years prior to clinical signs of NMO [48], and an inflam-
matory disease, such as gastroenteritis, is anecdotally re-
ported to precede clinical NMO disease.
After evaluating several maneuvers to produce NMO
pathology in seropositive rats, we found that a single
needle insertion into brain parenchyma was sufficient to
produce robust lesions around the needle track, with
the characteristic pathological features of human NMO
including loss of AQP4, GFAP and myelin, vasculo-
centric deposition of activated complement, granulocyte
and macrophage infiltration, and blood–brain barrierdisruption. Significant pathology was absent in rats
administered non-NMO human IgG. The absence of
significant pathology in similarly treated rats receiving
NMO-IgG but made complement-deficient by cobra
venom factor indicates the requirement for complement
in this model. It should be informative to evaluate the
roles of ADCC, neutrophils, eosinophils and macrophages
in this model, as done previously in other NMO models
[26,16,27-29,33], as well as to test therapeutics targeting
complement [37,38], NMO-IgG pathogenicity [35,36],
NMO-IgG binding to AQP4 [34,49], and leukocyte-
targeted drugs such as sivelestat [27] and cetirizine [29].
The NMO pathology seen at 5 days after intracerebral
needle injury in seropositive rats was around the needle
track in an area corresponding to that of early NMO-
IgG diffusion. At one day astrocyte damage with loss of
AQP4 and GFAP was seen, but little myelin loss. Inte-
restingly, at one day multifocal punctate lesions were
also seen away from the needle track that disappeared
by five days. These lesions may represent mild, reversible
astrocyte injury. A recent paper reported diffuse punc-
tate lesions in ~60% of seropositive rats injected with
IL-1β, but without lesions around the needle track [18].
In that study the level of NMO patient-derived IgG in
rat serum was not measured, though it was likely to be
quite low, as a single intraperitoneal injection of 10 mg
of NMO patient-derived IgG in rat is much lower than
75 mg used in our study, which was chosen to produce
serum cytotoxicity similar to that in human NMO. We
speculate that the substantially lower serum NMO-IgG
concentration in the study of Kitic et al. [18] was
responsible for absence of robust NMO pathology.
Conclusions
A robust, passive-transfer model of NMO was estab-
lished involving intracerebral needle stab injury in rats
made seropositive by IP administration of NMO-IgG.
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ment or pro-inflammatory factors, or pre-existing in-
flammation. The model should be useful for further
evaluation of NMO pathogenesis mechanisms and for
evaluation of NMO therapeutics targeting circulating
NMO-IgG, NMO-IgG binding to AQP4, complement,
and inflammatory cells and factors.
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